Flores v. Secretary of Health and Human Services ( 2021 )


Menu:
  •     In the United States Court of Federal Claims
    OFFICE OF SPECIAL MASTERS
    No. 18-0759V
    UNPUBLISHED
    SARAH FLORES and RYAN C.                                    Chief Special Master Corcoran
    FLORES, on behalf of M.F., a Minor
    Child,                                                      Filed: May 11, 2021
    Petitioners,                           Special Processing Unit (SPU);
    v.                                                          Damages Decision Based on Proffer;
    Measles Mumps Rubella (MMR)
    SECRETARY OF HEALTH AND                                     Vaccine; Thrombocytopenic Purpura
    HUMAN SERVICES,                                             (ITP)
    Respondent.
    Diana Lynn Stadelnikas, Maglio Christopher & Toale, PA, Sarasota, FL, for Petitioner.
    Kyle Edward Pozza, U.S. Department of Justice, Washington, DC, for Respondent.
    DECISION AWARDING DAMAGES1
    On May 30, 2018, Sarah and Ryan C. Flores filed a petition for compensation
    under the National Vaccine Injury Compensation Program, 42 U.S.C. §300aa-10, et seq.2
    (the “Vaccine Act”), on behalf of their minor daughter, M.F. Petitioners allege that
    following the June 23, 2016 administration of a measles, mumps and rubella (“MMR”)
    vaccine, M.F. experienced immune thrombocytopenic purpura (“ITP”). See generally
    Petition. The case was assigned to the Special Processing Unit of the Office of Special
    Masters.
    On February 1, 2021, a ruling on entitlement was issued, finding Petitioners
    entitled to compensation for ITP. On May 7, 2021, Respondent filed a proffer on award of
    1  Because this unpublished decision contains a reasoned explanation for the action in this case, I am
    required to post it on the United States Court of Federal Claims' website in accordance with the E-
    Government Act of 2002. 
    44 U.S.C. § 3501
     note (2012) (Federal Management and Promotion of Electronic
    Government Services). This means the decision will be available to anyone with access to the
    internet. In accordance with Vaccine Rule 18(b), Petitioner has 14 days to identify and move to redact
    medical or other information, the disclosure of which would constitute an unwarranted invasion of privacy.
    If, upon review, I agree that the identified material fits within this definition, I will redact such material from
    public access.
    2 National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 
    100 Stat. 3755
    . Hereinafter, for ease
    of citation, all “§” references to the Vaccine Act will be to the pertinent subparagraph of 42 U.S.C. § 300aa
    (2012).
    compensation (“Proffer”) indicating Petitioners should be awarded a lump sum payment
    of $1,844.13 for past unreimbursable expenses as well as an amount not to exceed
    $40,000.00, for actual pain and suffering, to purchase an annuity contract pursuant to the
    terms set forth in the Proffer. Proffer at 3-4. In the Proffer, Respondent represented that
    Petitioners agree with the proffered award. Id. Based on the record as a whole, I find that
    Petitioners are entitled to an award as stated in the Proffer.
    Pursuant to the terms stated in the attached Proffer, I award the following
    compensation:
    A. A lump sum payment of $1,844.13 representing compensation for past
    unreimbursable expenses, in the form of a check payable to Petitioners.
    B. An amount not to exceed $40,000.00, representing compensation for actual
    pain and suffering, to purchase an annuity contract paid to the life insurance
    company (the “Life Insurance Company”) from which the annuity will be
    purchased. The Life Insurance Company will agree to make lump sum
    payments to M.F. for all elements of compensation which M.F. would be
    entitled under Section 15(a) as follows:
    1. A certain lump sum of $13,061.14 payable on April 15, 2033.
    2. A certain lump sum of $21,575.90 payable on April 15, 2036.
    3. A certain lump sum of $22,822.02 payable on April 15, 2038.
    The purchase price of the annuity shall neither be greater nor less than
    $40,000.00. In the event that the cost of the certain lump sum annuity payments
    set forth above varies from $40,000.00, the lump sum payment due on April 15,
    2038, listed above, shall be adjusted to ensure that the total cost of the annuity
    is neither less than nor greater than $40,000.00. Should M.F. predecease the
    payment of any certain lump sums set forth above, any remaining certain lump
    sum payments shall be made to her estate. However, written notice to the
    Secretary of Health and Human Services and the Life Insurance Company shall
    be provided within twenty (20) days of M.F.’s death.
    This amount represents compensation for all damages that would be available under
    Section 15(a).
    The clerk of the court is directed to enter judgment in accordance with this
    decision.3
    3 Pursuant to Vaccine Rule 11(a), entry of judgment can be expedited by the parties’ joint filing of notice
    renouncing the right to seek review.
    2
    IT IS SO ORDERED.
    s/Brian H. Corcoran
    Brian H. Corcoran
    Chief Special Master
    3
    IN THE UNITED STATES COURT OF FEDERAL CLAIMS
    OFFICE OF SPECIAL MASTERS
    ____________________________________
    )
    SARAH FLORES and RYAN C. FLORES, )
    on behalf of M.F., a minor child,   )                No. 18-759V
    )                Chief Special Master Corcoran
    Petitioners,          )                ECF
    )
    v.                           )
    )
    SECRETARY OF HEALTH AND             )
    HUMAN SERVICES,                     )
    )
    Respondent.           )
    )
    RESPONDENT’S PROFFER ON AWARD OF COMPENSATION
    On May 30, 2018, Sarah Flores and Ryan C. Flores (“petitioners”), on behalf of M.F., a
    minor, filed a petition for compensation under the National Childhood Vaccine Injury Act of
    1986, 42 U.S.C. § 300aa-1 et seq. (“the Vaccine Act”). The petition alleges that M.F. received
    the measles, mumps, rubella (“MMR”) vaccine on June 23, 2016, and thereafter suffered
    idiopathic thrombocytopenic purpura (“ITP”). On January 19, 2021, the Secretary of Health and
    Human Services (“respondent”) filed an Amended Rule 4(c) Report advising that, in light of
    Chief Special Master Corcoran’s Findings of Fact and Conclusions of Law, respondent did not
    dispute that petitioners had satisfied all legal prerequisites for compensation under the Vaccine
    Act. ECF No. 58. On February 1, 2021, Chief Special Master Corcoran issued a Ruling on
    Entitlement, finding that petitioners were entitled to vaccine compensation. 1 ECF No. 59.
    1
    Respondent has no objection to the amount of the proffered award of damages set forth herein.
    Assuming the Chief Special Master issues a damages decision in conformity with this proffer,
    respondent waives his right to seek review of such damages decision. However, respondent
    reserves his right, pursuant to 42 U.S.C. § 300aa-12(e), to seek review of the Chief Special
    Master’s October 26, 2020, Findings of Fact and Conclusion of Law and February 1, 2021,
    entitlement decision.
    1
    I.     Items of Compensation
    A.      Future Unreimbursable Expenses
    The parties agree that based upon the evidence of record, M.F. will not require future
    medical or rehabilitative care for her vaccine-related injury. Therefore, respondent proffers that
    petitioners should not be awarded future unreimbursable expenses on M.F.’s behalf under 42
    U.S.C. § 300aa-15(a)(1)(A). Petitioners agree.
    B.       Lost Future Earnings
    The parties agree that based upon the evidence of record, M.F. will not suffer a loss of
    earnings capacity as a result of her vaccine-related injury. Therefore, respondent proffers that
    petitioners should not be awarded anticipated loss of earnings on M.F.’s behalf under 42 U.S.C.
    § 300aa-15(a)(3)(B). Petitioners agree.
    C.      Pain and Suffering
    Respondent proffers that M.F. should be awarded compensation for actual pain and
    suffering for her vaccine-related injury under 42 U.S.C. § 300aa-15(a)(4). Such compensation
    shall be in the form of an annuity as set forth in section II.B. below. The parties agree that it is
    unlikely that M.F.’s vaccine-related injury will cause her pain and suffering in the future.
    Petitioners agree.
    D.      Past Unreimbursable Expenses
    The parties agree that based upon the evidence of record, petitioners incurred past
    unreimbursable expenses of $1,844.13 as a result of M.F.’s vaccine-related injury. Therefore,
    respondent proffers that petitioners should be awarded past unreimbursable expenses on M.F.’s
    behalf under 42 U.S.C. § 300aa-15(a)(1)(B). Such compensation shall be in the form as set forth
    in section II.A. below. Petitioners agree.
    2
    E.       Medicaid Lien
    The parties agree that there is no Medicaid Lien.
    II.      Form of the Award
    Based upon the evidence of record, respondent proffers, and the parties recommend, that
    compensation be made through a combination of a lump sum and future annuity payments as
    described below, and request that the Chief Special Master’s decision and the Court’s judgment
    award the following:
    A.       A lump sum payment of $1,844.13 representing compensation for past
    unreimbursable expenses, in the form of a check payable to petitioners.
    B.       An amount not to exceed $40,000.00 to purchase an annuity contract,2 paid to the
    life insurance company 3 from which the annuity will be purchased (the "Life Insurance
    Company"). 4 The Life Insurance Company will agree to make lump sum payments to M.F. for
    all elements of compensation to which M.F. would be entitled under 42 U.S.C. § 300aa-15(a)
    §300aa-15(a), as follows:
    2
    In respondent’s discretion, respondent may purchase one or more annuity contracts from one or more life insurance
    companies.
    3
    The Life Insurance Company must have a minimum of $250,000,000 capital and surplus, exclusive of any
    mandatory security valuation reserve. The Life Insurance Company must have one of the following ratings from
    two of the following rating organizations:
    a. A.M. Best Company: A++, A+, A+g, A+p, A+r, or A+s;
    b. Moody's Investor Service Claims Paying Rating: Aa3, Aa2, Aa1, or Aaa;
    c. Standard and Poor's Corporation Insurer Claims-Paying Ability Rating: AA-, AA, AA+, or
    AAA;
    d. Fitch Credit Rating Company, Insurance Company Claims Paying Ability Rating: AA-, AA,
    AA+, or AAA.
    4
    Petitioners authorize the disclosure of certain documents filed by the petitioners in this case consistent with the
    Privacy Act and the routine uses described in the National Vaccine Injury Compensation Program System of
    Records, No. 09-15-0056.
    3
    1. A certain lump sum of $13,061.14 payable on April 15, 2033.
    2. A certain lump sum of $21,575.90 payable on April 15, 2036.
    3. A certain lump sum of $22,822.02 payable on April 15, 2038.
    The purchase price of the annuity described in this section II.B shall neither be greater nor
    less than $40,000.00. In the event that the cost of the certain lump sum annuity payments set forth
    above varies from $40,000.00, the lump sum payment due on April 15, 2038, listed above, shall
    be adjusted to ensure that the total cost of the annuity is neither less than nor greater than
    $40,000.00. Should M.F. predecease the payment of the any certain lump sums set forth above,
    any remaining certain lump sum payments shall be made to her estate. However, written notice to
    the Secretary of Health and Human Services and the Life Insurance Company shall be provided
    within twenty (20) days of M.F.’s death. Petitioners agree. 5
    5
    At the time payment is received, M.F. will be an adult, and thus guardianship is not required.
    4
    Respectfully submitted,
    BRIAN M. BOYNTON
    Acting Assistant Attorney General
    C. SALVATORE D’ALESSIO
    Acting Director
    Torts Branch, Civil Division
    HEATHER L. PEARLMAN
    Acting Deputy Director
    Torts Branch, Civil Division
    /s/ Kyle E. Pozza_____________
    KYLE E. POZZA
    Trial Attorney
    Torts Branch, Civil Division
    U.S. Department of Justice
    P.O. Box 146
    Benjamin Franklin Station
    Washington, D.C. 20044-0146
    Phone: (202) 616-3661
    Fax: (202) 353-2988
    Kyle.Pozza@usdoj.gov
    Dated: May 7, 2021
    5
    

Document Info

Docket Number: 18-759

Judges: Brian H. Corcoran

Filed Date: 6/14/2021

Precedential Status: Non-Precedential

Modified Date: 6/14/2021